Subject search results
1 Document(s) [ Subject: Food and Drug Administration, U.S. ]
|House Public Health
|Border crossings | Border issues | Border security | Dental Examiners, Texas State Board of | Dentists | Ebola | Food and Drug Administration, U.S. | Foster care | Immunizations | Medical records | Pharmaceutical industry | Pharmacies | Pregnancy | Prenatal care | Prescription drugs | Psychoactive drugs | Substance abuse | Unaccompanied minors | Undocumented immigrants | Workers' compensation | Workforce Commission, Texas |
|Library Call Number:
|83rd R.S. (2013)
|View report [82 pages]
|This report should address the charges below.
|Assess the prevalence of nonmedical prescription drug use in the state (including opioid analgesics, stimulants, tranquilizers, and sedatives). Identify adverse health impacts. Recommend strategies to curb emerging substance abuse trends among children, pregnant women, and adults, as well as to reduce health care costs and mortality.
|Study and make recommendations for improvements to the licensing, regulation, and monitoring of compounding pharmacies, including a review of the joint cooperative efforts between the Texas State Board of Pharmacy, Department of State Health Services, and U.S. Food and Drug Administration. Consider the impact of the passage of SB 1100, 83rd R.S., additional appropriations made by the 83rd Legislature to strengthen inspections, and any relevant federal legislation.
|Identify strategies to support the efficient exchange of electronic health information with Texas Health and Human Services enterprise agencies. Examine legal and technical issues around the accessibility of information held in registries maintained by state agencies to authorized health care providers. Identify issues related to health information exchange and providers' liability, as well as concerns related to transitioning patient data in cases where a provider selects a new electronic health record vendor.
|Examine the current practice for dispensation of biologic and follow-on biologic (biosimilar) pharmaceutical products in our state. Review any practices for interchangeability of drugs that might pertain to these particular medicines. Review and make recommendations regarding the substitution of biosimilar and biologic medicines.
|Monitor transition of the state's immunization registry to a new system. Determine whether the registry can be better utilized to prevent and/or respond to communicable disease outbreaks, including pertussis. Identify potential factors contributing to the rise in the number of pertussis cases and strategies to prevent future outbreaks.
|Conduct legislative oversight and monitoring of the agencies and programs under the committee’s jurisdiction and the implementation of relevant legislation passed by the 83rd Legislature, including HB 15, 83rd R.S.. In conducting this oversight, the committee should: a. consider any reforms to state agencies to make them more responsive to Texas taxpayers and citizens; b. identify issues regarding the agency or its governance that may be appropriate to investigate, improve, remedy, or eliminate; c. determine whether an agency is operating in a transparent and efficient manner; and d. identify opportunities to streamline programs and services while maintaining the mission of the agency and its programs.
Information on this website is provided as a public service by the Legislative Reference Library. The Legislative Reference Library makes no representation as to its completeness or accuracy and makes no warranty in regard to its use. Users assume all risk of reliance on the information included on this site.